U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07131449) titled 'Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies' on July 15.

Brief Summary: 4. Study Population 4.1 Inclusion Criteria Case group

1)>= 18 years old , regardless of gender; 2)Hematological malignancies confirmed by cytology, histology , or molecular biology , who require subsequent anti-tumor treatment ( chemotherapy , hematopoietic stem cell transplantation, radiotherapy, or cellular immunotherapy ) ; control group

1. >= 18 years old , regardless of gender;

2. Non-cancer patients undergoing health checkups;

4.2 Exclusion criteria

1. Pregnant women

2. Those with severe mental disorders ...